TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A University of Michigan-led study reports that experimental compound DT-109 reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models. The researchers say it reduced harmful gut bacteria and ammonia, helping protect the intestinal barrier and limit inflammatory substances reaching the liver. The results are preclinical; benefits and safety in people have not been established.
Researchers at the University of Michigan report that experimental compound DT-109 reversed features of severe fatty liver disease in animal studies by changing gut bacteria and strengthening the intestinal barrier. The findings, published in The Journal of Clinical Investigation, point to a possible gut-based approach to metabolic dysfunction-associated steatohepatitis, or MASH, but do not show that the drug works in people.
In experiments involving mice and nonhuman primates, DT-109 reduced levels of Clostridium perfringens, a gut bacterium that produces ammonia. The researchers say the resulting drop in intestinal ammonia helped protect the gut lining, limiting the movement of microbial products into the bloodstream and reducing signals that can inflame the liver.
The study describes a chain linking the gut to liver injury. When ammonia damages the intestinal barrier, substances produced by microbes can pass into the body and reach the liver. The researchers also reported excessive activation of CD8+ T cells, immune cells that can contribute to inflammation when overactive. DT-109 was associated with changes in these processes and with less liver inflammation and milder MASH in the primate experiments.
The work builds on earlier animal research in which the team found that DT-109 could improve MASH, while the mechanism was not yet clear. The new study offers evidence for how the compound may act: it primarily affects the gastrointestinal tract, with effects extending to the liver through the gut-liver connection. The source report does not describe human trial results.
A Gut-Based Route to Liver Protection
MASH can cause liver inflammation and cell damage and may progress to cirrhosis, liver cancer or liver failure. The source report estimates that the condition affects about 7% of the global population. Treatment options have improved, but effective therapies remain limited, making new approaches relevant to patients and researchers.
DT-109 is notable because the reported target is not only damage inside the liver. The findings suggest that changing gut bacteria and protecting the intestinal barrier may reduce some of the inflammatory material reaching the liver. That could help researchers investigate disease processes earlier in the chain, rather than focusing solely on established liver injury. However, animal improvements do not establish clinical benefit, and the study does not show that DT-109 can prevent complications or replace existing care.
gut health supplements for liver support
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Gut-Liver Link Fits
The liver receives blood carrying substances absorbed from the digestive tract, creating a biological connection often called the gut-liver axis. Changes in gut microbes or in the intestinal barrier can influence what reaches the liver. In this study, the researchers focused on ammonia-producing C. perfringens and the possibility that a weakened barrier allows microbial products to contribute to inflammation.
DT-109 is described as a glycine-based tripeptide, a small molecule made from three amino acids. The research team had previously reported beneficial effects in animal studies. The latest work adds an explanation for those effects and includes nonhuman primates, whose liver biology and microbial communities are described in the report as more similar to humans than those of mice. Those similarities can inform research but cannot substitute for human testing.
“We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression.”
— Eugene Chen, senior author and professor of cardiovascular medicine at the University of Michigan Medical School
probiotics for fatty liver disease
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Benefits Remain Unproven
The reported findings are from animal models; the source material provides no results from human trials. It is not clear whether DT-109 would have the same effects in people, what dose might be appropriate, or what risks could emerge with longer use. The report also does not provide enough detail to assess the size or durability of the benefits across the animal experiments.
Although the authors describe the results as promising, the study does not establish that the compound is a treatment for patients, nor does it show that it reverses MASH in humans. Any claims about use beyond liver disease, including possible cardiovascular applications mentioned in earlier animal research, also remain unconfirmed in people.
As an affiliate, we earn on qualifying purchases.
Human Testing Is the Key Milestone
The next major step would be research that tests safety and effects in people. The supplied report does not state whether clinical trials are planned, when they might begin, or whether DT-109 has entered any stage of human testing. Until those details and results are available, the work remains an early-stage animal finding.
Readers should look for any announcement of human studies, including their design, participant groups, safety findings and measures of liver improvement. For now, the research offers a possible mechanism and a candidate for further study, not a proven treatment or a reason to change medical care.
ammonia reducing gut health products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is DT-109?
DT-109 is an experimental glycine-based tripeptide studied for its effects on MASH. In the reported animal experiments, it acted mainly in the gastrointestinal tract.
Did DT-109 reverse fatty liver disease in people?
No human results are reported. The study found improvements in animal models, including mice and nonhuman primates. Whether the compound benefits people remains unknown.
How is the gut involved in the findings?
The researchers say DT-109 reduced ammonia-producing C. perfringens and helped protect the intestinal barrier. That may limit microbial products entering the bloodstream and contributing to liver inflammation.
What is MASH?
MASH, or metabolic dysfunction-associated steatohepatitis, is a serious form of fatty liver disease involving excess liver fat, inflammation and cell damage. It can progress to cirrhosis and other severe complications.
Is DT-109 available as a treatment?
The source report describes DT-109 as experimental and provides no evidence that it is approved or available to treat patients. People should consult a qualified health professional about medical decisions.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
